目的 研究生血宁片联合蛋白琥珀酸铁口服溶液治疗妊娠期缺铁性贫血的临床疗效。方法 选取2018年6月—2019年6月在天津市宝坻区人民医院治疗的67例妊娠期缺铁性贫血患者，将所有患者随机分为对照组（34例）和治疗组（33例）。对照组患者饭前口服蛋白琥珀酸铁口服溶液，1瓶/次，2次/d。治疗组在对照组基础上口服生血宁片，2片/次，3次/d。两组患者接受4周治疗。观察两组的临床疗效，比较两组血液学指标、铁代谢指标、贫血发生率、早产率和产后出血率。结果 治疗后，对照组和治疗组的总有效率分别为76.47%、93.94%，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清铁（SI）、转铁蛋白饱和度（TSAT）显著升高（P<0.05），且治疗组SI、TSAT明显高于对照组（P<0.05）。治疗后，两组患者血红蛋白（Hb）、红细胞计数（RBC）、平均红细胞体积（MCV）、平均血红蛋白浓度（MCHC）均显著升高（P<0.05）；且治疗组Hb、RBC、MCV、MCHC均高于对照组（P<0.05）。治疗后，治疗患者贫血发生率、早产率、产后出血率明显低于对照组（P<0.05）。结论 生血宁片联合蛋白琥珀酸铁口服溶液治疗妊娠期缺铁性贫血具有较好的临床疗效，能够改善血液学指标和铁代谢指标，降低贫血发生率、早产率、产后出血率，值得在临床上推广应用。

Objective To evaluate the efficacy of Shengxuening Tablets combined with Iron Proteinsuccinylate Oral Solution in treatment of iron deficiency anemia during pregnancy. Methods Patients (67 cases) with iron deficiency in Baodi District People’s Hospital of Tianjin from June 2018 to June 2019 were randomly divided into the control group (34 cases) and the treatment group (33 cases). Patients in the control group were po administered with Iron Proteinsuccinylate Oral Solution before meals, 1 bottle /time, twice daily. Patients in the treatment group were po administered with Shengxuening Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and hematology indexes, iron metabolism indexes, the incidence of anemia, premature delivery and postpartum hemorrhage in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 76.47% and 93.94%, respectively, and there was difference between two groups (P<0.05). After treatment, SI and TSAT of the two groups were significantly increased (P<0.05), and the SI and TSAT of the treatment group were significantly higher than those of the control group (P<0.05). After treatment, Hb, RBC, MCV, and MCHC of the two groups were significantly increased (P<0.05), and Hb, RBC, MCV, and MCHC in the treatment group were higher than those in the control group (P<0.05). After treatment, the incidence of anemia, premature delivery, and postpartum hemorrhage in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shengxuening Tablets combined with Iron Proteinsuccinylate Oral Solution has clinical curative effect in treatment of iron deficiency anemia during pregnancy, can improve hematological indexes and iron metabolism indexes, reduce the incidence of anemia, premature delivery rate and postpartum hemorrhage rate, which is worthy of clinical application.

R973；R984